About QurAlis
QurAlis is a Healthcare company based in Cambridge (United States) founded in 2016 by Clifford J Woolf and Kasper Roet. Drugs and CSF devices are developed for ALS treatment. QurAlis has raised $155.45 million across 7 funding rounds from investors including Amgen, EQT and HHS. The company has 38 employees. Its chief executive, as recorded, is Kasper Roet. QurAlis offers products and services including FlexASO® Platform and QRL-101. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is QURALIS CORPORATION. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.27.3 channel CSF cartridge device to remove DPR proteins.
- Headquarters Cambridge, United States
- Employees 38
- Founders Clifford J Woolf, Kasper Roet
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website quralis.com
- Social LinkedIn X
- Legal Name Quralis Corporation
- Total Equity Funding$155.45M (USD)
in 7 rounds
- Latest Funding Round$19.95M (USD), Series B
Aug 2025
- InvestorsAmgen
& 18 more
- Employee Count38
Products & Services of QurAlis
QurAlis offers a comprehensive portfolio of products and services, including FlexASO® Platform and QRL-101.
Proprietary platform for anti-sense oligonucleotide therapies
Therapy targeting Kv7 for ALS treatment
Funding Insights of QurAlis
QurAlis has successfully raised a total of $155.45M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $19.95 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155.45M
- Total Rounds 7
- Last Round Series B — $19.95M
- First Round $5.5M
(Apr 2018)
- Investors Count 19
All 7 funding rounds of QurAlis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $19.95M | Series B | – | – | – |
| Mar 2023 | $88M | Series B | – | EQT, Sanofi Ventures | |
| Sep 2022 | $300,000 | Grant | – | – | |
| Jul 2020 | $107,420 | Grant | – | – | |
| May 2020 | $42M | Series A | – | Polaris Partners, Mission BioCapital | |
| Sep 2019 | $224,119 | Grant | – | – | |
| Apr 2018 | $5.5M | Seed | – | Amgen Business Development, MP Healthcare Venture Management | – |
19 investors in total: 19 institutional.
Investors in QurAlis
QurAlis has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, EQT and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Droia Ventures is focused on investing in drug development companies. | droiaventures.com | Luxembourg, Luxembourg | ||
A venture capital fund focused on biotech for neurodegeneration. | alsinvestmentfund.com | Amsterdam, Netherlands | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
AI, deeptech, and healthcare tech companies are funded by Inkef. | inkef.com | Amsterdam, Netherlands | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
A venture capital firm focused on life science innovations. | mp-healthcare.com | Cambridge, United States |
Investor details for QurAlis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of QurAlis
50 people are tracked at QurAlis (18 in leadership, 18 in board & advisors, 14 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Clifford J Woolf | Founder | Leadership |
Kasper Roet | Founder & CEO | Leadership |
Manoj Malhotra | Chief Medical Officer | Leadership |
Megan Johnson | Associate Director, Clinical Operations | Leadership |
Guzide Adhikari (Icke) | Vice President, Global Supply Chain | Leadership |
Chris Thomajan | Chief Financial Officer | Leadership |
Meredith Ball | Vice President, Human Resources | Leadership |
Emma Bowden | Senior Vice President, Head Of Clinical Development | Leadership |
Daniel Elbaum | Chief Scientific Officer | Leadership |
Vikas Sharma | Chief Business Officer | Leadership |
Hagen Cramer | Chief Technology Officer | Leadership |
Xihui Xu | Senior Director Of Toxicology | Leadership |
Shirley Lasch | Head, Business Operations | Leadership |
Kristine Kelly | Senior Director Finance | Leadership |
Halima Tanous Edd | Associate Director, Business Administration | Leadership |
Clarida E. Martinez | Director, Clinical Operations | Leadership |
Sandy Hinckley | Vice President, Head Of Discovery | Leadership |
Praveen Kumar Pogula | Director, DS | Leadership |
Brian J. Wainger | Scientific Advisor | Board & advisors |
Christopher Shaw | Scientific Advisor | Board & advisors |
30 more people are available in the full profile.
Complete people profiles for QurAlis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of QurAlis
3 dated milestones of QurAlis across 9 years, from founding to its latest funding, stage changes and deals.
- Founded QurAlis is founded.
- Funding First funding round of $5.5M.
- Funding Latest funding round, Series B, of $20.0M.
Competitors of QurAlis
QurAlis has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of QurAlis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of QurAlis
The website of QurAlis (quralis.com) receives about 4K visits a month.
- Monthly visits4K
▲ 79.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as QurAlis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Quralis
Complete news archive for QurAlis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QurAlis
QurAlis was founded in 2016 and raised its 1st funding round 2 years after it was founded.
QurAlis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Kasper Roet is the CEO of QurAlis, as recorded in our data. They have also founded this company.
QurAlis is a funded company, having raised a total of $155.45M across 7 funding rounds to date. The company's 1st funding round was a Seed of $5.5M, raised on Apr 2018.
QurAlis has 38 employees.
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.27.3 channel CSF cartridge device to remove DPR proteins.
QurAlis's top competitors include BridgeBio, Forge Biologics and Insitro.
QurAlis offers FlexASO® Platform and QRL-101.
QurAlis has 19 investors. Key investors include Amgen, EQT, HHS, Life Sciences Partners, and Viva BioInnovator.
QurAlis operates through Quralis Corporation.